^
    Back
    Association details:
    Biomarker:KRAS Q61H
    Cancer:Sarcoma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Natl Compr Canc Netw
    Title:

    Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation

    Published date:
    03/24/2022
    Excerpt:
    This report presents the first patient with histiocytic sarcoma harboring a somatic KRAS Q61H mutation who was subsequently treated to a near complete response with the MEK inhibitor trametinib.
    DOI:
    10.6004/jnccn.2022.7001